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KARISHMA SMART 
ABSTRACT 
 Parkinson’s disease (PD) is a neurodegenerative disease that causes 
degeneration of nigral dopaminergic terminals in the caudate and the putamen 
regions of the striatum in the basal ganglia.  According to current practice, when 
an unequivocal clinical diagnosis of PD cannot be made, a single-photon 
emission computed tomography scan using the DaTscan radionuclide (SPECT 
DaT scan) is ordered.  However, the assessment of SPECT DaT scans in the 
diagnosis of PD depends on the subjective judgment of a radiologist, which can 
pose problems for the accuracy of the diagnosis.  Furthermore, as research 
studies generally do not quantify SPECT DaT scans when using them, their 
conclusions are not based on standardized data.  The aim of this paper is to 
propose a method of quantification for SPECT DaT scans, to be employed in 
diagnostic and research environments.  The methodology proposed in this thesis 
project will eventually be used for a much larger multimodal imaging project 
investigating the connectivity changes in the brain related to cognitive and 
affective symptoms in PD patients.  Each of the 4 subjects in this project 
underwent a SPECT DaT scan and an MPRAGE scan (Magnetization Prepared 
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Rapid Gradient Echo), an anatomical MRI (magnetic resonance image).  The 
SPECT DaT scans and the MPRAGEs were coregistered, and then a voxel-
based quantification of the caudate and the putamen in the left and the right 
hemispheres was performed in every subject.  First, the percentages of voxels 
with intensities exceeding various pericalcarine baselines were calculated.  A 
pericalcarine baseline was used because the pericalcarine gyrus in the occipital 
lobe has been shown to have little to no dopaminergic activity, particularly on 
SPECT DaT scans.  Next, asymmetry indices (AI) were calculated for two of the 
thresholds whereby the ratio of the percentage of voxels in the right to the left 
hemispheric region was taken.  Wilcoxon Signed-Rank tests and bootstrapping 
analyses were performed on both the caudate and the putamen in all four 
subjects to determine the significance of any detected asymmetry.  The 
quantification of the data and the AI values revealed asymmetries in the voxel 
intensities between the left and right hemispheres.  This asymmetry was 
consistent with each subject’s side of physical symptom onset.  According to the 
bootstrapping analyses, this asymmetry was significant in five of the eight 
comparisons.  In summary, this methodology has potential to bring greater 
objectivity to the use of SPECT DaT scans in the diagnosis of PD and in 
research through its anatomically accurate, voxel-based quantification. 
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INTRODUCTION 
 
General Background of Parkinson’s Disease 
 Parkinson’s disease (PD) is a neurodegenerative disease in which 
dopaminergic neurons idiopathically start to dysfunction, leading to a wide variety 
of symptoms, ranging from loss of motor function to increased anxiety to 
dementia (1, 2).  Currently, the majority of what is understood about PD deals 
with the motor aspect of the disease, and, until very recently, the diagnosis was 
entirely based on visible motor symptoms (2).  Unfortunately, such a diagnostic 
method is less than ideal.  It relies on the neurologist’s judgment, which often 
requires considerable experience, and the overlap of symptoms found in PD and 
other movement disorders, such as Essential Tremor (ET) and drug-induced 
Parkinsonism, lends itself to misdiagnosis and error (2, 3). 
 In 2011, the US Food and Drug Administration (FDA) approved the use of 
single-photon emission computed tomography (SPECT) scans to aid in 
distinguishing ET from PD (4).  Since then, there has been increasing research 
into the efficacy of SPECT imaging in distinguishing PD from other Parkinsonian 
disorders, but the general method remains the same: a radiologist qualitatively 
determines the abnormality of the scan – based on asymmetrical dopaminergic 
uptake in the two striates – to confirm or deny a diagnosis of PD (5).  Just as with 
the diagnostic method used by neurologists, the reading of SPECT scans is 
hardly an exact science and relies heavily on the radiologist’s subjective 
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judgment (2).  Subtle asymmetry can easily be missed, which can prevent an 
accurate PD diagnosis from being made until later in the disease (2). 
 Although the current use of the SPECT scan to aid in the diagnosis of PD 
relies on motor symptoms already being present, a more accurate interpretation 
of these scans could help to identify PD in its early stages, when the motor 
symptoms are still too mild for a clear diagnosis.  This could lead to starting 
treatment earlier in the disease, which has been shown to improve symptoms 
and slow the progression of PD.  Quantifying the SPECT scans should allow for 
a less qualitative assessment of PD in a patient with a questionable diagnosis 
from a neurologist. 
 
History of Parkinson’s Disease 
 Although Parkinson’s disease is by no means a recent disease – sources 
describe elements of the disease as early as the 12th century BC (6) – it was not 
until the early 19th century that the disease was first reported in a scientific 
capacity.  At that time, there were a number of published accounts of PD-like 
symptoms, which inspired Dr. James Parkinson in 1817 to write about six cases 
in his own experience that involved symptoms consistent with PD (1).  He titled 
this seminal paper “An Essay on the Shaking Palsy”, and it is widely considered 
the first comprehensive description of the disease.  Indeed, for such a small 
sample size, only two subjects of which actually entered Dr. Parkinson’s practice, 
the essay is impressively accurate (1).  The disease was known as paralysis 
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agitans (shaking palsy) until the late 19th century when Dr. Jean-Martin Charcot, 
considered the “father of modern neurology” (1), moved to change the name to 
Parkinson’s disease. 
 
Medical/Biological Background of Parkinson’s Disease 
Neurological Basis of PD 
 Classically, PD is understood as being caused by dysfunction and 
degeneration of dopamine (DA) neurons in the substantia nigra of the basal 
ganglia, which in turn affects their connections to various other parts of the brain, 
causing the wide range of symptoms seen in PD (1, 2).  The degenerating 
neurons accumulate Lewy bodies (LBs); the presence of these LBs in the basal 
ganglia upon autopsy is the only current method of unequivocal diagnosis (1, 2).  
LBs are pathological cytoplasmic aggregates of alpha-synuclein that disrupt cell 
function surrounded by a coating of ubiquitin protein, which tags proteins for 
destruction (7). 
The basal ganglia, of which there is one in each hemisphere of the brain, 
is a collection of subcortical nuclei and comprises of five main structures: the 
globus pallidus, the subthalamic nucleus, the nucleus accumbens, the substantia 
nigra, and the striatum (which is further subdivided into the caudate and the 
putamen) (1, 7).  All the structures are involved in some way in the motor system, 
but they are also associated with a number of non-motor functions that can be 
affected in PD patients (7).  For example, the nucleus accumbens is influential in 
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reward and motivation, particularly in regards to the motor system, and serves to 
increase the likelihood of a particular behavior through the expectation of reward 
(7).  Parkinsonian dysfunction in the nucleus accumbens and the striatum is 
believed to be related to the increased impulsivity and onset of impulse control 
disorders seen in PD patients (7, 8).  The globus pallidus and the substantia 
nigra help to modulate movement control by inhibiting unwanted movements, 
particularly in the face, through their tonic inhibition of the thalamus (8).  The 
subthalamic nucleus also helps to suppress movement sequences through its 
excitatory inputs to the globus pallidus and the substantia nigra (7).  Not 
surprisingly, therefore, the two prime targets for deep brain stimulation implant 
surgery (DBS) are the subthalamic nucleus and the globus pallidus (3).  In DBS 
surgery, a remote-controlled stimulation device is implanted in one of these two 
areas and helps to artificially modulate unwanted movements, often greatly 
improving PD symptoms (3). 
The striatum, the last of the aforementioned basal ganglia structures, 
receives cortical input and relays it to other areas of the basal ganglia (7).  In the 
case of movement, the current understanding is that input from the motor cortex 
initiating a movement is relayed to striatal subregions, which then activate the 
particular striatopallidal pathway necessary for the desired motion; the pallidal 
inhibition of thalamic neurons is thus released (7).  The rest of the tonically 
inhibitory pallidothalamic pathways are unaffected by the striatal output, and, in 
fact, the subthalamic nucleus often simultaneously activates its excitatory 
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pathways to the globus pallidus and substantia nigra to ensure suppression of all 
other pathways save for the one striatally activated (7).  It is believed that non-
motor pathways that involve the basal ganglia follow a similar model in that they 
receive cortical inputs and relay them back to relevant cortical targets (7).  For 
example, the caudate is considered to be a part of the oculomotor, dorsolateral, 
and ventral/orbital cortico-striatal loops, whereas the putamen is involved in the 
sensorimotor circuit (9). 
The basal ganglia contain both excitatory and inhibitory circuits (1, 7).  
One of the primary ways in which the nigral dopamine neurons dysfunction in PD 
is a decline in DA production and release, which upsets the careful balance of 
excitation and inhibition, leading to the variety of symptoms seen in PD patients 
(1).  Over time, the dysfunction of existing nigral neurons turns into degeneration 
of those neurons (1).  Thus, although medications have been shown to improve 
symptoms and, in some cases, maybe slow the progression of the disease, they 
eventually lose significant efficacy as PD progresses (1).  This neuronal 
degeneration in the basal ganglia is not unnatural – around 5% of neurons die 
every decade after the age of 20.  Thus, although some neuronal loss is 
expected with aging (7, 8), the advanced rate at which it occurs in patients with 
PD is pathological (1, 7).  In fact, patients generally do not start to show 
Parkinsonian symptoms until 50% of the substantia nigra’s dopaminergic 
neurons have degenerated (7), corresponding to about an 80% loss of striatal 
dopamine (8). 
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Motor Symptoms 
Today, the four cardinal symptoms associated with PD are bradykinesia, 
rigidity, resting tremor, and postural instability (2, 3).  Often, a PD diagnosis is 
made if at least two of the first three symptoms (bradykinesia, rigidity, and resting 
tremor) are present (3), though the most common diagnostic criteria for PD, the 
UK Brain Bank criteria, requires that one of these two symptoms be bradykinesia.  
As postural instability is commonly seen in the elderly population and often does 
not appear until the later stages of PD, many clinicians do not consider postural 
instability when assessing a PD diagnosis (3).  Another common feature of the 
disease is its asymmetric presentation of tremor, rigidity, and bradykinesia.  
Other common motor symptoms include gait disturbances, hypophonia 
(decreased vocal volume), hypomimia (diminished facial expression), and 
micrographia (small, cramped handwriting) (3). 
 Bradykinesia technically refers to the slowing of movement seen in PD 
patients, but the term can also be used to describe more generally bradykinesia, 
hypokinesia (smaller movements), or akinesia (lack of movement) (3).  It has 
been shown to be closely correlated with loss of dopamine in the putamen and 
shows the greatest improvement with dopaminergic therapy.  Interestingly, 
patients often also exhibit kinesia paradoxical reactions, where the typical 
bradykinesia temporarily dissipates in response to stress, such as being able to 
run out of a burning building (3).  This supports the theory that PD motor 
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symptoms are due to compromised access to regulatory motor programs rather 
than deficits in the motor cortex or its connections to peripheral motor circuits (3). 
Rigidity is increased muscle stiffness and is due to increased muscle tone 
unrelated to movement.  For example, when a patient relaxes a joint, which 
would normally allow for easy passive movement by the examiner, the joint 
remains stiff and difficult to rotate.  Muscle rigidity also commonly exhibits a 
positive response to dopaminergic therapy (3). 
The most well known feature of PD is resting tremor.  Unlike forms of 
tremor seen in other conditions, resting tremor, as the name implies, is observed 
when the affected part of the body is at rest and disappears when the body part 
is being used (3).  This is contrary, for example, to Essential Tremor, a benign 
movement disorder, where the tremor only appears when the body part is active.  
Commonly, in PD, the tremor starts in an upper extremity, and the classic 
example is a “pill rolling” tremor in the hand, where the thumb and index fingers 
rolls back and forth against each other as if rolling a pill between them (3).  
Tremor is less closely correlated with striatal dopamine loss, so it is less 
responsive to dopaminergic therapy than either bradykinesia or rigidity (3). 
Although postural instability is not used to diagnose PD, it is a common 
late-stage symptom that contributes to patients’ risk of dangerous falls (3).  To 
test for this symptom, the examiner stands behind the patients and tugs them 
backward by the shoulders to pull them off balance; a healthy person can regain 
balance in one backward step, whereas PD patients require multiple steps to 
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catch themselves (3).  The Unified Parkinson’s Disease Rating Scale (UPDRS), 
for example, defines three or more backwards steps as pathological (10).  In 
severe cases, the patient may not be able to move their feet back at all to catch 
themselves (3). 
There are other symptoms that, although not evidence of PD in 
themselves, the presence of which can corroborate a PD diagnosis.  One type of 
symptom that can support a diagnosis of PD is gait disturbance, which can 
manifest in a number of ways (3).  Many patients begin to shuffle, often dragging 
the leg on the affected side of the body, and maintain a flexed posture, which is 
seen as a perpetual bending over forward.  Others can exhibit difficulties initiating 
gait movements or changing gait directions (3). A poorly understood feature is 
gait freezing, where the patient inexplicably freezes in the middle of walking, 
often when changing direction or crossing a threshold, such as passing through a 
doorway.  A second type of corroborating symptom is the decreased amplitude of 
certain aspects of motor function (3).  One example is the hypomimia that some 
patients experience, where their emotional range is intact, but their ability to 
express their emotions facially (due to hypokinesia of facial musculature) has 
been compromised (3, 11).  Other examples include the micrographia not 
uncommonly exhibited by patients in late-stage PD (3) and severe cases of 
hypophonia, in which patients may be unable to speak louder than a whisper (3).   
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Non-Motor Symptoms: Psychiatric and Autonomic 
 Aside from the characteristic motor symptoms, patients with PD can 
experience a number of non-motor symptoms as well.  These can be of a 
neuropsychiatric or autonomic nature (3).  Often, these symptoms are more 
disabling for patients than their motor ones; unfortunately, most of these 
symptoms can be attributed to other diseases, and so their association with PD is 
still gaining recognition (3). 
 The neuropsychiatric symptoms can include depression, anxiety, apathy, 
dementia, and impulsivity.  Depression is the most common psychiatric symptom 
and often precedes the onset of the PD diagnosis.  The profile of depression in 
PD patients is also different than in patients suffering from primary depression, 
such as fewer feelings of guilt and self-reproach (3, 12).  Apathy, as well as 
social withdrawal and anhedonia (loss of interest in previously enjoyed activities), 
are also more common in patients with PD-related depression (3, 13).  Anxiety, 
which is nearly as common as depression and is distinct from the stress derived 
from being diagnosed with PD, can present in up to 40% of patients (3, 14).  
Dementia is quickly becoming recognized as a part of PD, though it tends to 
present much later in the disease’s progression (15).  Interestingly, Dr. James 
Parkinson confidently described PD with the “intellects being uninjured” (1); 
however, it is now known that patients with PD are six times more likely to 
develop dementia than their age-matched peers (3).  Finally, impulsivity has 
been documented as more common in patients with PD than in controls.  This 
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lack of impulse control can appear as problems with gambling, shopping, eating, 
and changes in sexual behavior (3).  Impulse control disorders, when they are a 
symptom of PD, are believed to be a result of mesolimbic dopaminergic system 
dysfunction arising from the dopaminergic deficiency caused by the disease (3); 
however, paradoxically, they can also be caused by dopaminergic therapy for the 
pharmacological treatment for PD (3).  (Please refer to the sections Medication 
Therapy and Side Effects of Medication Therapy for further explanation.) 
 Patients with PD can also experience sleep disturbances due to their 
disease.  The most common sleep disorder associated with PD is REM behavior 
disorder, in which patients act out their dreams, often violently, which can disturb 
both their own and their bed partner’s sleep (3).  Although REM behavior 
disorder is not a symptom of PD, it precedes PD in nearly 40% of cases (3). 
 The autonomic symptoms can include pain, dysphagia (difficulty 
swallowing), and urinary and olfactory dysfunction (3).  A meta-analysis 
suggested that dysphagia may be present in up to one third of PD patients. In 
addition to impeding the swallowing of medication tablets, dysphagia has been 
linked to an increase in risk of pneumonia, which is a main cause of death in PD 
patients (16).  In PD, urinary dysfunction usually presents as incontinence.  This 
is believed to be due to the loss of striatal dopamine, particularly in the putamen, 
in basal ganglia circuits that normally inhibit micturition (emptying the bladder) 
(7).  Finally, pre-motor olfactory dysfunction (i.e. presenting before the onset of 
motor symptoms) most often presents as hypoosmia – loss of the sense of smell 
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– presumably due to the degrading connections between the olfactory bulb and 
the substantia nigra (3). 
 
Medication Therapy 
 Currently, the most common and the oldest pharmacological treatment of 
PD is levodopa, or L-dopa.  Approved by the FDA in 1967, its continued efficacy 
affirms its wide consideration as a “miracle drug” (1).  As PD is primarily a 
disease of dopaminergic degeneration, L-dopa was developed quite logically 
being that dopa is the natural precursor to dopamine in the body.  With the idea 
that exogenous dopamine could mitigate the effects of PD dopamine loss, L-
dopa was developed as dopa can cross the blood-brain barrier while dopamine 
cannot (1).  L-dopa is usually given as a levodopa-carbidopa combination (called 
Sinemet) in which the carbidopa acts to prevent peripheral transformation of 
dopa into dopamine.  The addition of carbidopa maximizes the amount of dopa 
that actually crosses the blood-brain barrier as well as prevents side effects of 
increased peripheral dopamine, such as nausea, vomiting, and hypotension (1).  
Once in the brain, L-dopa is taken up pre-synaptically by DA neurons where 
intracellular enzymes convert it into DA to be released (1).  However, L-dopa 
does not cure PD, and eventually the diseases progresses, albeit more slowly, to 
a point where there are not enough functioning neurons in which L-dopa can be 
stored and converted to dopamine (1). 
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 In an effort to minimize L-dopa dosage to extend its efficacy, Sinemet is 
often given in combination with a DA agonist.  DA agonists bind predominantly to 
D2 receptors in the basal ganglia to stimulate the post-synaptic receptors in the 
absence of naturally produced DA (1).  Despite being generally less well-
tolerated, DA agonists do have certain advantages over L-dopa: as DA agonists 
act post-synaptically, they continue to be a viable pharmacological therapy after 
L-dopa’s efficacy diminishes due to the paucity of DA neurons (1). 
 
Side Effects of Medication Therapy 
 Another complication of PD is that the medication therapy can cause its 
own side effects that mirror PD symptoms.  A common example is that impulse 
control disorders can be due to PD or dopaminergic therapy (3).  In a healthy 
individual, endogenous DA binds equally to D1 and D2 receptors; however, the 
DA agonists currently available have a much greater affinity for D2 receptors.  
Additionally, the disproportionately greater stimulation of D2 receptors occurs 
phasically, peaking each time the medication is taken (1).  This effectively mimics 
the phasic DA release associated with the expectation of reward without the 
subsequent signal suppression that normally engages when the anticipated 
reward is not received.  This dysregulation of the reward system by DA agonists 
is responsible for the impulse control disorders caused by dopaminergic therapy 
(1). 
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Dopaminergic therapy can also produce side effects that would not have 
otherwise been seen in the natural progression of PD.  A common side effect that 
patients often have to contend with is the dyskinesia that L-dopa can introduce 
(1).  Dyskinesia is involuntary, abnormal movements, often seen as writhing or 
wiggling movements in the limbs and face (3).  It is believed that this side effect 
is due to hypersensitivity of dopamine receptors arising from dopamine levels 
that are disproportionately high compared to the dwindling numbers of basal 
ganglia neurons (1). 
 
Background of Diagnostic Methods 
UK Brain Bank Criteria 
Currently, PD must be clinically diagnosed, most commonly by the UK 
Brain Bank criteria, which were delineated by the UK Parkinson’s Disease 
Society (3). According to these criteria, a PD diagnosis requires the presence of 
bradykinesia in concurrence with rigidity, rest tremor, postural instability, or any 
combination thereof as well as overall disease progression (though the rate can 
vary widely) (3).  In addition, there is very often unilateral onset and subsequent 
persistent asymmetry of symptoms.  Patients with PD also usually show a 70-
100% positive response to L-dopa treatment at first, and, in fact, a lack of 
response to L-dopa can be considered suggestive of a non-PD Parkinsonism (3).  
This is because a lack of response to L-dopa probably indicates that basal 
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ganglia dopaminergic neuron dysfunction is not involved in the etiology of the 
patient’s symptoms. 
 
Issues with Clinical Diagnosis Methods 
 Although a clinical diagnosis by a movement disorder specialist is 
considered the “gold standard” (1), one factor that can compromise its efficacy is 
that the diagnostic process is fairly qualitative and therefore subject to human 
error.  Another undermining factor is that, in practice, many diagnoses of PD are 
actually made by general neurologists who do not have the same specific 
expertise as movement disorder specialists.  These two factors contribute to the 
25% misdiagnosis rate of PD (3, 5).  Misdiagnoses in PD come in two flavors: 
patients with another Parkinsonian disorder incorrectly diagnosed as PD and 
patients with PD incorrectly diagnosed with another Parkinsonian disorder. 
 Parkinsonian disorders are often grouped into two categories based on 
whether the symptoms are due to an extrapyramidal neuron dysfunction in the 
basal ganglia (3).  Basal ganglia function is preserved in the non-
neurodegenerative Parkinsonian disorders, which include Essential Tremor (ET), 
drug-induced Parkinsonism, and vascular Parkinsonism (3).  ET is a benign 
movement disorder involving a tremor that only appears during motion.  Drug-
induced Parkinsonism is usually caused by prolonged exposure to 
antidopaminergic drugs.  Vascular Parkinsonism presents with PD-like symptoms 
that are due to lesions or ischemic damage localized in the basal ganglia (3). 
 15 
Atypical Parkinsonism, which includes multiple system atrophy (MSA), 
progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is 
also due to basal ganglia dysfunction (3).  There are certain symptoms that if 
present may suggest an alternate diagnosis.  For example, postural instability 
and falls tend to appear late in PD but present early in PSP (3).  Another 
example is persistent asymmetry.  PD’s initially unilateral presentation ultimately 
becomes bilateral, whereas CBD’s marked asymmetry lasts much longer (3).  
Although these kinds of symptoms may theoretically facilitate the differential 
diagnosis of Parkinsonian syndromes, they can take time to present.  This often 
delays both a correct diagnosis and the initiation of appropriate treatment (3).  
Additionally, presentations of each disease vary widely.  To further complicate 
the matter, Parkinsonian symptoms can deviate from those expected of their 
syndromes and can sometimes present similarly to other Parkinsonian diseases 
(3, 5).  Indeed, it might be that only by observing the intrinsic underlying brain 
changes can an unequivocal diagnosis be determined. 
 
Unified Parkinson’s Disease Rating Scale 
The UPDRS is used as a clinical rating scale to assess the severity of a 
patient’s PD.  The most recent version has six parts that address the various 
domains of Parkinsonian symptoms (3).  The original UPDRS included only Parts 
I-IV: Parts I, II, and III deal with, respectively, neuropsychological symptoms, 
symptoms affecting daily life such as excessive salivation and micrographia, and 
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motor symptoms, and Part IV addresses complications of pharmacologic therapy 
(3).  Part V is a modified Hoehn and Yahr staging scale, which identifies the 
patient’s stage of PD, and Part VI is the Schwab and England Activities of Daily 
Living Scale, which estimates the patient’s percentage of independence in daily 
living activities.  Both scales are concerned principally with motor function (3). 
 
MRI Scans 
General Information 
 Magnetic resonance imaging (MRI) is a form of imaging that uses strong 
magnetic fields, rather than the nuclear radiation of single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET) scans, 
to produce 3D representations of the brain (18).  The patient is placed inside a 
large magnetic coil that forms a large uniform magnetic field.  This magnetic field 
is oscillated, applying the resultant energy to the area of interest, which is 
absorbed by the hydrogen atoms in water molecules (18).  These excited protons 
emit radio waves that are detected by the scanner and used to determine the 
proton’s location (18).  The excited protons decay back to their equilibrium state 
– their energy level prior to the magnetic field induction – at different rates 
according to characteristics of the particular tissue they comprise.  These 
variations produce a contrast between areas in the image that allows for 
differentiation of distinct tissues (18). 
 17 
 An important feature of neuroimaging, particularly in MRIs, is the 
segmentation of the image into voxels.  Just as pixels are uniform 2D areas that 
make up a larger 2D image, such are voxels for a 3D space.  The use of voxels 
in neuroanalysis allows for more standardization in image interpretation. 
 
MPRAGE 
Magnetization Prepared Rapid Gradient Echo (MPRAGE) is an MRI 
technique that rapidly acquires T1-weighted 3D images of the brain using 
magnetization pulse sequences (19).  These inversion pulses increase the signal 
intensity, producing an image with high resolution and clear contrast.  Thus, 
MPRAGE is well-suited to image neuroanatomy unlike functional scans such as 
SPECT (19). 
 
Limitations to Use of MPRAGE in PD Imaging 
 Despite the widespread applicability that MPRAGE has enjoyed, its 
suitability in imaging PD has not been convincingly demonstrated (1, 5).  
Generally, MPRAGE has not shown any structural changes in PD, and any 
visible atrophy has not been specific enough to identify PD (1).  However, other 
neurodegenerative diseases have a characteristic pattern of structural atrophy, 
and so MPRAGE has been employed to differentiate other Parkinsonian 
disorders from PD (1).  
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SPECT Scans 
General Information 
 SPECT scanning is a form of nuclear medicine tomographic imaging used 
to produce 3D functional representations of the brain.  A radionuclide is injected 
into the patient, which is then used to produce the image (3).  Radionuclides are 
gamma-emitting radioisotopes, usually with a specific ligand attached, which 
release a single gamma photon that is detected by the scanner (5).  The scanner 
acquires multiple 2D images across the entire brain from different angles, and 
then a computer applies a tomographic reconstruction algorithm to the 2D 
images to produce a 3D representation of the brain (5). 
 SPECT DaT scans have been approved by the FDA for the differentiation 
of PD and ET, and they are used widely in PD research (4).  The DaT refers to 
the DAT protein that the scan’s radionuclide targets.  DAT is a pre-synaptic 
transporter on dopaminergic neurons in the caudate and putamen that re-
uptakes DA from the synapse to be recycled (5, 7).  The radionuclide used 
diagnostically is 123I-Ioflupane, marketed as DaTSCAN.  DaTSCAN contains a 
radioligand that binds to the dopamine transporter (DAT) (5).  When the 
DaTSCAN radioligand binds to DAT, it releases a gamma photon.  As PD 
progresses, there are fewer dopaminergic neurons with DAT, and so the scan 
detects fewer gamma photons (1).  Therefore, indirectly the scan detects the 
presence of DAT and by association the integrity of nigrostriatal dopamine 
pathways (1).  There are radionuclides that bind to the post-synaptic D2 receptor 
 19 
and measure function based on the number of receptors, which is up- or down-
regulated according to dopaminergic activity.  However, the number of pre-
synaptic transporters provides a more accurate estimation of relevant 
dopaminergic function, as it is the pre-synaptic neurons’ diminishing dopamine 
production that forms the etiological basis of PD (1). 
 
Advantages 
 The inclusion of SPECT DaT scanning in the study and diagnosis of PD 
brings a number of advantages.  Many studies have shown the high sensitivity 
and specificity of DaTSCAN in the differentiation of PD from other Parkinsonian 
disorders, particularly those without extrapyramidal degeneration (2, 3).  There is 
strong evidence that the availability of DAT as measured with DaTSCAN reflects 
striatal dopamine levels (5, 20).  Furthermore, these DaTSCAN measures also 
correlate with disease severity (3).  At the moment, PD can only definitively be 
diagnosed upon autopsy (though, in practice, a “gold standard” diagnosis is 
treated as close to definitive) because the accumulation of LBs responsible for 
PD is not visible without brain dissection (1).  Although SPECT DaT cannot 
detect LBs, it allows for disease assessment on a much deeper level etiologically 
than a purely clinical exam through the visualization of underlying dopaminergic 
brain changes (1). 
As there is often ambiguity from which disease a patient’s Parkinsonian 
symptoms stem, a SPECT DaT scan can reveal the extent of striatal dopamine 
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loss, providing valuable information for a diagnosis (2, 5).  Studies looking at the 
SPECT DaT scans of patients with PD and age-matched healthy controls have 
found clear differences in striatal dopamine loss, as have studies comparing PD 
patients with those suffering from non-extrapyramidal Parkinsonian disorders (2, 
5).  In fact, SPECT DaT has been shown to have 95% specificity and sensitivity 
in differentiating PD from ET (2, 3).  Limited research into SPECT DaT imaging of 
atypical Parkinsonian disorders has suggested different patterns of striatal 
dopamine loss in MSA, PSP, and PD.  Further investigation could reveal 
identifying patterns of degeneration to better differentiate within this group of 
idiopathic Parkinsonian diseases (1, 2). 
 
Limitations 
 Despite the potential SPECT DaT has for improving diagnostic ability and 
expanding our understanding of PD, it has two important limitations that must be 
considered when addressing its use: poor resolution and subjective assessment.  
The first limitation is the SPECT scan’s poor resolution.  Unlike PET scans, 
whose radionuclides release two gamma photons for superior localization, the 
single gamma photon of SPECT scans severely reduces the resolution (1, 2).  
Outside of the vaguely defined striatal areas illuminated in the scan, SPECT DaT 
provides negligible anatomical detail, which poses a serious problem for their 
interpretation (5). 
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 Some studies have attempted to mitigate the problem of SPECT DaT’s 
poor resolution by coregistering the image to a scan with much greater 
resolution.  Seibyl et al. developed a methodology whereby the SPECT DaT scan 
of each PD patient was coregistered to a composite MPRAGE image made up of 
the anatomical scans from four healthy controls in a previous study (21).  A 
number of studies have since employed this methodology in their work (20), but it 
is seriously flawed in that the composite MPRAGE and the SPECT DaT came 
from different people.  Thus, any differences in anatomy between the two scans 
were ignored.  Importantly, if the anatomical location of the composite image’s 
striatum is not exactly the same as in the patient, then any results regarding 
striatal activation in the SPECT DaT scan are compromised. 
 The second limitation in the current diagnostic use of SPECT DaT scans 
is the general lack of quantification (2).  When a SPECT DaT scan is read 
clinically, the radiologist qualitatively judges the asymmetry of activation in the 
striatal areas, usually without any anatomical localization or a healthy scan for 
comparison (3).  Indeed, there is very little consensus of what constitutes 
“abnormal” enough to merit a PD diagnosis.  Just as the manifestation of PD 
symptoms varies widely across the patient population, so too does, in all 
probability, the extent of degeneration that elicits the onset of PD (1).  In some 
clinical settings, the signal detected in highly activated striatal areas, less 
activated striatal areas, and extra-striatal areas are compared to determine the 
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extent of dopamine loss.  However, this methodology is not standardized, and 
the comparison remains fairly qualitative (5). 
 Some studies have begun to incorporate basic quantification into their 
methodology but so far only for research purposes.  Marek et al. simply used the 
average striatal uptake of dopamine (based on the binding of the radionuclide) as 
a quantitative measure (20).  Seibyl et al. calculated a striatal binding ratio 
(SBR), the ratio of the average striatal uptake to the average uptake in the 
occipital lobe, an extra-striatal region with typically very little to no DAT activity 
(21).  Ravina et al. built on the Seibyl et al. method and reported the percent 
change in SBR between different time period and between PD patients and 
controls (22).  However, all three of these methods average dopaminergic uptake 
over large areas, which masks any subregional differences. 
 
Proposed Improvements 
 Though the lack of quantification and the poor resolution are currently 
important concerns regarding the use of SPECT DaT, they are certainly issues 
that can be improved upon.  A higher resolution image would allow for more 
precise localization of activated areas, and a more quantitative assessment of 
the images would increase the accuracy and relevance of the scan’s 
dopaminergic measures.  Once these concerns are addressed and their effects 
mitigated, SPECT DaT scans have a very promising future in deepening our 
understanding of PD and improving diagnostic accuracy.  This project aims to 
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address just these two issues.  The SPECT DaT scans were coregistered to the 
subject’s own MPRAGE to improve the scan’s resolution while increasing 
confidence in the accuracy of anatomical location.  The quantification is voxel-
based and does not average across the entire region.  Thus, it should reveal any 
significant subregional variation that may be lost with such averaging. 
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The Current Project 
 The context for this thesis is a larger project (Development of a New 
Multimodal Imaging Technique Involving Striato-Frontal Structural, Functional, 
and Dopaminergic Connectivity to Study the Progression of Cognitive Decline in 
Parkinson’s Disease), which aims to use the quantification method developed in 
this thesis in conjunction with diffusion tensor imaging (DTI) white matter 
tractography, functional connectivity MRI (fcMRI) seed-based analysis, and 
neuropsychological testing to study the brain changes in structural, functional, 
and dopaminergic connectivity between the striatum and cortical areas that relate 
to cognitive and affective symptoms in patients with PD.  DTI white matter 
tractography uses directional information about water diffusion in brain tissue to 
delineate the structural white matter tracts in the brain.  The fcMRI seed-based 
analysis identifies brain areas that are functionally connected to a pre-specified 
seed region based on the concurrence of similar blood-oxygen level changes. 
 The goals of this larger project are twofold.  The first is to develop a new 
methodology combining multimodal imaging and neuropsychological 
assessments with which to improve future study of cognition and mood in 
patients with Parkinson’s disease.  The second is to build upon the current 
understanding of the etiology of cognitive and affective changes seen in PD with 
more comprehensively integrated neurological and behavioral investigation.  The 
hope is that, eventually, this method and the results therein can be used towards 
development of predictive abilities for various cognitive and affective symptoms, 
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such as dementia and depression, in PD patients.  As a result, patients 
diagnosed with PD may benefit from earlier interventions and possibly even 
preventative measures for their predicted symptoms. 
 This thesis project, however, is more clinically directed.  The aim of this 
thesis project is to develop a method with which to quantify diagostic SPECT 
DaT scans.  The hope is that this method can be used to increase the objectivity 
of PD diagnosis through neuroimaging.
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METHODS 
 
Overview 
 The four participants whose data contributed to this thesis were patients 
suffering from Parkinson’s disease.  The overall purpose of this study was to 
develop and present a method for the quantification of SPECT scans, which are 
used in the differential diagnosis of Parkinson’s disease.  For each subject, an 
MPRAGE MRI scan and a SPECT DaT scan were obtained.  Using the 
FreeSurfer image processing and analysis software (publicly available at 
http://surfer.nmr.mgh.harvard.edu), the MPRAGE and the SPECT scans were 
coregistered.  Labels were drawn delineating the caudate and the putamen within 
the striatum of each hemisphere.  The total number of voxels and the number of 
voxels exceeding particular intensity thresholds in each label were quantified 
using various statistical analyses.  Please refer to the Quantification section of 
the Methods. 
 
Patient Recruitment 
 All four subjects were patients of Dr. Raymon Durso at the Boston VA 
Movement Disorders Clinic.  He briefly discussed the project with his Parkinson’s 
disease patients who had undergone a SPECT scan, and, if they indicated 
interest, he forwarded their contact information to the lab.  The participant was 
then recruited over the phone for the Cognition and Parkinson’s Project, but their 
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data was also used for this thesis project.  When each patient arrived for his first 
scheduled visit of the project, formal consent for his participation was acquired, in 
which the details of the study and his involvement were explained to him.  The 
Institutional Review Board of the VA Boston Healthcare System in Jamaica Plain 
approved access to medical records of patients who provided consent; this 
included medical histories and brain scans acquired for clinical purposes.  
Although the patients returned for other visits, only the visits involving the 
consenting process and the MRI scan were relevant to this thesis.  The MRI scan 
was part of the same visit as that of the consent acquisition – the first visit – for 
all but one of the four subjects.  The SPECT DaT scan, on the other hand, had 
been ordered previously by Dr. Durso for clinical purposes.  In conjunction with 
the acquisition of formal consent, an MRI safety screening was also done to 
ensure the patients were eligible to undergo an MRI scan.  For one patient, an X-
ray was required for MRI clearance, which was also ordered by Dr. Durso. 
 
Patient Information 
 The four patients were primarily recruited for the Cognition and 
Parkinson’s Project, which is looking at religiosity and cognition in patients with 
PD.  Every patient had a subject number for the Cognition and Parkinson’s 
Project; however, in the interest of increased protection of patient confidentiality, 
they have each been given a number from 1 through 4 for this thesis project. 
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 In addition to the MPRAGE and the SPECT DaT scan acquired for each 
subject, three pieces of information regarding the subject’s disease were 
collected.  The Hoehn & Yahr stage of each subject was collected from Dr. 
Durso, the neurologist and PD expert associated with the lab.  The patient was 
asked for the number of years since his PD diagnosis and the side of onset on 
which his disease initially presented.  Each patient’s Hoehn & Yahr stage and the 
number of years since initial diagnosis of PD were used to assess disease 
severity. 
 
SPECT Imaging 
 SPECT DaT scans were used to determine the extent of dopaminergic 
loss in the striatal subregions of interest.  Each patient had undergone a SPECT 
scan out of clinical necessity to confirm a Parkinson’s disease diagnosis.  Dr. 
Durso referred all four patients after obtaining their SPECT scan and confirming 
their diagnosis.  Part of the consent the patients provided was to allow access to 
their SPECT scans. 
 SPECT scan images were acquired using a Philips Forte gamma camera 
at the Boston VA Medical Center in West Roxbury, MA.  Head motion was 
restricted with a head strap for minimal blurring due to motion.  The SPECT scan 
used the DaTscan radionuclide (I-123 Iofluopane), which binds to presynaptic 
dopamine transporters, primarily in the striatum.  The patient was injected with a 
thyroid blocker approximately 5 hours prior and with the radionuclide 
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approximately 4 hours prior to the scanning session.  As DaTscan contains 
iodine, the thyroid blocker is required to protect hyperactivation of the thyroid 
from the radionuclide.  Each image was 128x128 pixels and took about 30 
seconds; the scanner takes 128 images total over the course of an hour. 
 
MRI 
 All MR images were acquired using a Siemens MAGNETOM Trio 3-Tesla 
system with a 12-channel phased-array and body-coil transmission at the VA 
Medical Center in Jamaica Plain, Boston, MA.  Head motion, which can blur the 
images, was restricted using a thick foam pillow and adjustable padded clamps 
to restrain the head.  Earplugs were utilized to attenuate scanner noise and a 
mirror was attached to the headcoil to allow the subject to see outside the bore of 
the scanner.  Participant pulse and heart rate were monitored during imaging 
with a pulse oximeter. 
 
MPRAGE 
 MPRAGE was one of the scans obtained during MRI scanning sessions.  
Two 3D anatomical images were acquired for each patient with resolution of 
256x256 mm and field-of-view of 256x256 mm.  The scans had a repetition time 
(TR) of 2530 ms, an inversion time (TI) of 1100 ms, and an echo time (TE) of 
3.32 ms.  Each scan was comprised of 176 1-mm slices with 0.5 mm gaps and a 
flip angle of 7 degrees. 
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Image Pre-Processing 
MPRAGE was used to accurately visualize and identify the regions being 
explored.  The pre-processing of the MPRAGE scans, known as cortical 
reconstruction or recon-ing, was done with the FreeSurfer software. 
The entirely automated FreeSurfer recon process involves tessellation of 
the grey-white matter boundary (23) and surface deformation following intensity 
gradients to optimally place the grey/white and grey/cerebrospinal fluid (CSF) 
borders at the location where the greatest shift in intensity defines the transition 
to the other tissue class (24).  The non-brain tissue is removed (25), and 
magnetic field gradient non-linearity (25) and topology (23) are corrected for.  A 
white matter segmentation and a cortical parcellation are produced based on 
probabilistic models of tissue MR parameters and of known anatomical locations 
(26; 27).  
The white matter segmentation was used to help identify the location of 
the striatal activation, or lack thereof, in the SPECT scans.  A radiologist at the 
Boston VA Jamaica Plain campus was consulted about the automatic 
segmentation.  He corroborated the accuracy of the automated procedure in one 
subject and provided direction on how to verify the accuracy of the other three 
scans so that the correct areas in each subject were investigated. 
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Coregistration 
Although coregistration of MRI and SPECT has been done previously 
(28), the novel method proposed in this project involves the coregistration of a 
SPECT scan to the subject’s own MPRAGE.  The coregistration of images was 
done using BBRegister, a tool within FreeSurfer that uses a boundary-based cost 
function to align two sufficiently different images from the same subject (29).  
BBRegister automatically creates a registration matrix that essentially warps one 
image into the space of another so that they can be analyzed together (29).  
Coregistering the SPECT DaT to the subject’s own MPRAGE permitted us to 
accurately locate anatomy as well as create a common space for these otherwise 
very different scans.  After each automated registration with BBRegister, the 
results were checked with FreeView, FreeSurfer’s viewing tool. 
 
Neuroanatomical Labeling 
 The labels used in the quantification were drawn in the FreeSurfer tool 
Freeview, using its drawing tool.  The automatic segmentation (aseg) volume 
created in the recon-all process served as a guide by identifying the areas of 
interest based on the MPRAGE.  The labels were drawn on the SPECT DaT 
volume by using the drawing tool to highlight relevant voxels.  The label files 
contained the 3D (x,y,z) coordinates and intensity values of each voxel.  In each 
subject, six labels (three in each hemisphere) were drawn: the caudate, the 
putamen, and the pericalcarine gyrus.  The striatum in each hemisphere was 
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represented in the SPECT DaT image as red or yellow to indicate the high 
intensity of these highly innervated dopaminergic areas.  However, the aseg 
volume offered much greater accuracy in anatomical localization.  This increased 
the confidence that the intensity values being studied were indeed striatal.  The 
pericalcarine gyrus, which is a cortical area in the occipital lobe (22), served as a 
dopaminergic baseline in the quantification; as there is little to no dopaminergic 
activity in the pericalcarine gyrus (22), the intensities of its voxels were low due to 
the lack of bound radionuclide. 
 
Quantification 
 The voxel-based quantification of the SPECT scans was done using the 
intensity information contained as output in the label files.  First, general 
information was calculated for each region.  The total number of voxels in each 
region was reported.  The range and the range size were calculated for the 
striatal intensities in each region. 
Next, the intensities of the voxels in each of the pericalcarine gyri were 
averaged to produce a mean value for the baseline.  The number of voxels and 
the percentage of voxels in each of the caudate and the putamen that exceeded 
various thresholds were calculated.  These thresholds were the pericalcarine 
baseline and twice, triple, quadruple, five times, six times, and seven times that 
baseline.  This gave a more detailed idea of the extent to which each region 
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exceeds the pericalcarine baseline.  Using the total number of voxels in each 
region, the proportion of voxels that exceeded each level was reported. 
Finally, an asymmetry index was calculated for the two striatal regions 
whereby the ratio was taken of the proportion of voxels in the left hemisphere to 
right hemisphere that exceeded three and four times the pericalcarine baseline.  
These two thresholds were chosen because they are the highest levels above 
the baseline for which there were asymmetry index values (the ratio of the right 
hemisphere region intensity values to the left), respectively, for both regions in 
every subject and for both regions in at least 2 subjects.  These ratios were used 
for three purposes.  The first was to show that the asymmetry in the regions in 
each subject corresponded to the side of onset on which the patient’s disease 
initially presented.  The second was to show that the patients with asymmetry 
indices much greater than or less than 1 (i.e. a greater difference in intensity 
between the two hemispheres) had SPECT scans that appeared more 
asymmetrical in activation.  The third was to show that the region – caudate or 
putamen – with the smaller asymmetry index, indicating a greater unilateral 
deactivation, corresponded to greater degeneration of dopaminergic terminals 
from entering nigral DA neurons in that region as seen on the patient’s SPECT 
scan.  Here, the caudate and the putamen in each hemisphere were marked 
according to the MPRAGE by arrows in order to indicate the hemisphere with the 
greatest dopaminergic loss. 
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Statistics 
 The significance of the asymmetry revealed in the quantification was 
determined by Wilcoxon signed-rank tests, in which the region in the right 
hemisphere was compared to the same region in the left hemisphere.  The 
Wilcoxon signed-rank test is a non-parametric hypothesis test used to test the 
significance of the difference between two related samples based on a 
comparison of their population mean ranks.  In this case, the pairwise 
comparison involved subtracting the first voxel’s intensity in the right hemisphere 
label file from the first voxel’s intensity in the left hemisphere label file and then 
repeating this procedure for all the rest of the data pairs.  In other words, the 
absolute value difference in intensity for each voxel pair was calculated.  These 
differences were ranked and then signed; a negative sign indicated that the left 
hemispheric voxel had a greater intensity, and a positive sign indicated that the 
right hemispheric voxel had a greater intensity.  The mean rank was calculated 
separately for positively signed and negatively signed ranks.  Therefore, for all 
eight tests, a larger mean positive rank indicated greater voxel intensities in the 
right hemispheric region, and a larger mean negative rank indicated greater voxel 
intensities in the left hemispheric region.  A paired difference test was deemed 
appropriate because the two samples in each test were not independent: the two 
regions came from the same brain at the same time using the same measure.  A 
non-parametric test was required because the distribution of voxel intensities in 
each region was not assumed to be normal.  In fact, the more-affected 
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hemisphere’s regions were hypothesized to have voxel intensity distributions 
skewed towards lower values.  The Wilcoxon signed-rank tests were performed 
in SPSS [Version 22.0 (Released 2013); IBM Corp., Armonk, NY, USA] (30).  For 
each of the eight tests performed, the mean rank of each region, the critical 
value, and the p-value were reported. 
 As Wilcoxon signed-rank tests are paired difference hypothesis tests, they 
can only be run on complete pairs.  SPSS automatically truncated all the data 
that exceeds the lowest common number of complete pairs between samples.  
Thus, all incomplete pairs in the larger of the two regions were excluded from the 
analysis.  This exclusion posed a potential problem, as the Wilcoxon tests were 
not run on the complete data set.  The possibility exists that these excluded 
voxels, had they been included, would have changed the outcome of the 
hypothesis test.  To account for this issue, a bootstrapping analysis was 
performed on all eight contrast pairs within the four subjects.  The bootstrapping 
analysis was performed in MATLAB [Version 7.11.0.548 (R2010b) 64-bit (win64); 
The MathWorks, Inc., Natick, MA, USA] (31), in which a difference median and 
the associated confidence intervals around this median were calculated based on 
300,000 iterations of randomly selected samples, which matched the sample size 
used in the Wilcoxon tests.  If the random difference median of zero, which 
indicates the null hypothesis, fell inside the confidence interval around the 
difference median, then there was no significant difference between the samples.  
This meant that any significant difference that SPSS found was due to the data 
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being fortuitously truncated rather than to true significance.  If SPSS did not find 
a significant difference, then such a result would confirm this lack of significance.  
However, if this random median of zero fell outside the confidence interval for the 
calculated difference median, then there was a significant difference between the 
two samples.  This meant that any significant difference that SPSS uncovered 
was indeed legitimate.  If SPSS did not reveal any significant difference, but the 
bootstrap did, then the data truncated by SPSS must have contributed 
significantly to the difference median.
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RESULTS 
Patient Information 
Each patient was asked for the time since his initial diagnosis of PD and the 
side of onset on which his disease first presented.  His Hoehn & Yahr stage in his 
“on” state was determined by his neurologist, Dr. Raymon Durso, the PD expert 
in our lab.  A patient is considered to be in an “on” state when his PD 
medications are exerting an effect on his motor symptoms. 
 
Table 1. General Information about Each Subject. 
 Subject 1 Subject 2 Subject 3 Subject 4 
Side of Onset (of Motor 
Symptoms) 
Right Right Left* Right 
Hoehn & Yahr Stage 3 1 1 2 
Years Since Diagnosis 7 2 16 4 
*Subject 3’s side of disease onset has been debated.  The patient was initially 
diagnosed with left-body onset PD.  However, he had motor symptoms presenting on 
both sides of his body throughout his medical history.  After he was referred to the 
Neurology service at the Boston VA Hospital in Jamaica Plain (to the care of Dr. Durso), 
he underwent a SPECT scan.  The radiologist read the SPECT scan as revealing left 
putamen deactivation to indicate a right-body onset of PD.  The left-body onset was 
chosen for this project because it was the initial side of onset noted in the patient’s 
medical history.  This helped to maintain consistency, as the other three subjects’ side of 
onset listed was the initial side of onset clinically determined. 
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Quantification 
General Information About Each Region 
After each subject’s scans were coregistered, the caudate and putamen in 
each hemisphere were quantified.  Although the range of intensities, range size, 
and the total number of voxels differed in each subject, they were similar 
between each hemisphere’s caudate and putamen within every subject. 
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Table 2. General Information about Each Scan’s Caudate and Putamen 
Regions. 
 Left Caudate Left Putamen Right Caudate Right Putamen 
Range: 119-
879 
Range: 304-
988 
Range: 134-
911 
Range: 279-
1083 
Range Size: 
760 
Range Size: 
684 
Range Size: 
777 
Range Size: 
804 
Subject 1 
Total: 3429 Total: 5059 Total: 3149 Total: 5393 
 
Range: 97-
719 
Range: 99-728 Range: 49-746 Range: 121-746 
Range Size: 
622 
Range Size: 
629 
Range Size: 
697 
Range Size: 
625 
Subject 2 
Total: 4464 Total: 6074 Total: 3925 Total: 6144 
 
Range: 37-
248 
Range: 34-293 Range: 56-286 Range: 35-313 
Range Size: 
211 
Range Size: 
259 
Range Size: 
230 
Range Size: 
278 
Subject 3 
Total: 3788 Total: 5614 Total: 4453 Total: 5411 
 
Range: 36-
740 
Range: 132-
715 
Range: 44-589 Range: 158-601 
Range Size: 
704 
Range Size: 
583 
Range Size: 
545 
Range Size: 
443 
Subject 4 
Total: 3341 Total: 4488 Total: 3571 Total: 3829 
The range is the range of intensity values over an entire region.  The range size is the 
size of this range, and it was calculated by subtracting the lowest intensity value in a 
single region from the highest intensity value in the same region.  The total is the total 
number of voxels in a particular region. 
 40 
 
 
Pericalcarine Thresholds 
  The pericalcarine baseline in each hemisphere was determined by 
calculating the mean intensity of the pericalcarine gyrus on the SPECT scan. The 
percent of voxels whose intensities exceed two through seven times the 
pericalcarine baseline was reported in each region for each subject. The 
percentage exceeding the pericalcarine baseline was included for reference. The 
percentages here were based on the total number of voxels that exceed the 
particular threshold. 
 
Table 3. Percent of Voxels that Exceed Five Pericalcarine Baseline 
Thresholds in the Caudate and Putamen Regions in Subject 1. 
 Left Caudate Left Putamen Right Caudate Right Putamen 
Pericalcarine 
Baseline 
95.77 100 94.57 100 
2x Baseline 75.27 93.81 81.96 98.39 
3x Baseline 12.57 55.68 40.43 79.29 
4x Baseline 0 2.85 13.59 31.58 
5x Baseline 0 0 0 3.19 
6x Baseline 0 0 0 0 
7x Baseline 0 0 0 0 
The mean pericalcarine intensity, which served as the pericalcarine baseline, is 236.22 
for the left hemisphere and 204.30 for the right hemisphere. 
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Table 4. Percent of Voxels that Exceed Five Pericalcarine Baseline 
Thresholds in the Caudate and the Putamen Regions in Subject 2. 
 Left Caudate Left Putamen Right Caudate Right Putamen 
Pericalcarine 
Baseline 
98.61 99.87 99.03 100 
2x Baseline 79.75 89.04 88.10 94.39 
3x Baseline 66.02 72.98 76.76 58.69 
4x Baseline 45.18 46.87 65.96 30.26 
5x Baseline 22.29 22.42 52.23 16.15 
6x Baseline 0.11 2.24 22.14 6.32 
7x Baseline 0 0 7.52 2.33 
The mean pericalcarine intensity, which served as the pericalcarine baseline, is 119.64 
for the left hemisphere and 96.41 for the right hemisphere. 
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Table 5. Percent of Voxels that Exceed Five Pericalcarine Baseline 
Thresholds in the Caudate and Putamen Regions in Subject 3. 
 Left Caudate Left Putamen Right Caudate Right Putamen 
Pericalcarine 
Baseline 
99.23 99.96 99.64 98.50 
2x Baseline 71.09 85.04 57.44 77.05 
3x Baseline 27.01 56.36 24.34 45.09 
4x Baseline 6.81 36.02 11.18 26.83 
5x Baseline 1.35 15.32 1.66 9.41 
6x Baseline 0 1.53 0 0 
7x Baseline 0 0 0 0 
The mean pericalcarine intensity, which served as the pericalcarine baseline, is 45.49 for 
the left hemisphere and 53.21 for the right hemisphere. 
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Table 6. Percent of Voxels that Exceed Five Pericalcarine Baseline 
Thresholds in the Caudate and Putamen Regions in Subject 4. 
 Left Caudate Left Putamen Right Caudate Right Putamen 
Pericalcarine 
Baseline 
90.75 99.98 94.23 99.32 
2x Baseline 29.30 28.72 58.08 75.06 
3x Baseline 5.54 1.05 12.43 6.53 
4x Baseline 0 0 0 0 
5x Baseline 0 0 0 0 
6x Baseline 0 0 0 0 
7x Baseline 0 0 0 0 
The mean pericalcarine intensity, which served as the pericalcarine baseline, is 174.94 
for the left hemisphere and 211.45 for the right hemisphere. 
 
Asymmetry Indices 
The asymmetry index (AI) was calculated for each region as a ratio of the 
proportion of voxels in the right hemisphere to the proportion of voxels in the left 
hemisphere whose intensities exceed either three or four times the pericalcarine 
baselines.  For example, the AI of the caudate would be AI = no. of right 
hemisphere caudate voxels / no. of left hemisphere caudate voxels. 
There are no AI data for either the caudate or the putamen in Subject 4 for 
the higher threshold, as there were no voxels in either region whose intensity 
exceeded 4 or 5 times the pericalcarine baseline.  There are no AI data for the 
caudate in Subject 1 because there were no voxels in the left caudate whose 
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intensity exceeded quadruple the pericalcarine baseline, though there were such 
voxels in the right caudate. 
 
Table 7. Asymmetry Indices for the Proportions of Voxels that Exceed 
Triple and Quadruple the Pericalcarine Baseline in the Caudate and 
Putamen Regions in Subjects 1-4. 
  Subject 1 Subject 2 Subject 3 Subject 4 
Caudate 3.22 1.16 0.90 2.24 3x 
Pericalcarine 
Baseline Putamen 1.42 0.80 0.80 6.22 
Caudate N/A 1.46 1.64 N/A 4x 
Pericalcarine 
Baseline Putamen 11.08 0.65 0.74 N/A 
AI values that are greater than 1 indicate that there were more voxels in the right 
hemisphere region than in the left.  AI values that are less than 1 indicate that there were 
more voxels in the left hemisphere region than in the right. 
 
Scans 
The following images are single-slice axial views of a 3D image of each 
subject’s SPECT scan coregistered to his own MPRAGE.  The colors of the 
SPECT DaT represent the scan’s intensity, reflecting the amount of 
dopaminergic uptake: blue and green indicate, respectively, negligible and low-
level activity, whereas yellow and red indicate, respectively, high and extremely 
high levels of dopamine activity in the striatum.  The SPECT DaT also revealed 
the asymmetric dopaminergic activity of PD.  Three of the four subjects had right-
onset PD, which originates in the left hemisphere, and the fourth subject had left-
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onset PD originating in the right hemisphere.  All of this corresponded to the 
asymmetry seen in the quantification of the data.  The scans also reflected the 
localization of the dopaminergic loss – in other words, whether the caudate or 
putamen contributed more to the asymmetric deactivation – which was also 
supported by the quantification data.  All four scans are presented in the 
radiological convention whereby the left hemisphere is on the right side of the 
scan and vice versa. 
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Figure 1. Subject 1 – SPECT DaT Coregistered to MPRAGE. 
 
The white arrows are pointing to the left and right caudate.  The gold arrows are pointing 
to the left and right putamen.  The scan is in radiological view, so the left hemisphere is 
on the right side of the scan, and vice versa. 
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Figure 2. Subject 2 – SPECT DaT Coregistered to MPRAGE. 
 
The white arrows are pointing to the left and right caudate.  The gold arrows are pointing 
to the left and right putamen.  The scan is in radiological view, so the left hemisphere is 
on the right side of the scan, and vice versa. 
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Figure 3. Subject 3 – SPECT DaT Coregistered to MPRAGE. 
 
The white arrows are pointing to the left and right caudate.  The gold arrows are pointing 
to the left and right putamen.  The scan is in radiological view, so the left hemisphere is 
on the right side of the scan, and vice versa. 
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Figure 4. Subject 4 – SPECT DaT Coregistered to MPRAGE. 
 
The white arrows are pointing to the left and right caudate.  The gold arrows are pointing 
to the left and right putamen.  The scan is in radiological view, so the left hemisphere is 
on the right side of the scan, and vice versa. 
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Statistics 
 A Wilcoxon Signed-Rank test was performed on the intensity data derived 
from the caudate and the putamen of each subject’s brain.  For each of the eight 
tests, the mean rank for the positive ranks and for the negative ranks was 
reported, as well as the critical Z-value, the p-value, and the result of the 
hypothesis test.  The results of the related bootstrapping analyses are also 
provided in the form of a histogram. 
 
Subject 1 
In the caudate, the mean rank was significantly higher for the positive 
ranks, meaning that the left caudate had significantly higher voxel intensities.  In 
the putamen, the mean rank was significantly higher for the negative ranks, 
meaning that the right putamen had significantly higher voxel intensities. 
 
Table 8. Analysis Between Hemispheres of Subject 1 Using Wilcoxon 
Signed-Rank Test. 
Region 
Tested 
 
Mean Rank of 
Negative Ranks 
Mean Rank of 
Positive Ranks 
Critical Value P Value 
Caudate 1520.05 1631.37 Z= –3.712 p< 0.001 
Putamen 2638.29 2399.69 Z= –6.770  p< 0.001 
 
 According to the bootstrapping analysis, the left caudate had a 
significantly greater median as the null hypothesis median fell outside the left-
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side of the confidence interval around the difference median.  The right putamen 
had a significantly higher median than the left putamen as the null hypothesis 
median fell outside the right-side confidence interval around the difference 
median.  Thus, the bootstrapping analysis and the Wilcoxon test were in 
agreement regarding both the caudate and the putamen.
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Figure 5. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Caudate in Subject 1. 
 
The green H0 median is on the zero value of the x-axis, which is at the far left of the 
graph. 
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Figure 6. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Putamen in Subject 1. 
 
The green H0 median is on the zero value of the x-axis, which is at the far right of the 
graph. 
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Subject 2 
In the caudate, the mean rank was significantly higher for the positive 
ranks, meaning that the left caudate had significantly higher voxel intensities.  In 
the putamen, the mean rank was also significantly higher for the positive ranks, 
meaning that the left putamen had significantly higher voxel intensities. 
 
Table 9. Analysis Between Hemispheres of Subject 2 Using Wilcoxon 
Signed-Rank Test. 
Region 
Tested 
 
Mean Rank of 
Negative Ranks 
Mean Rank of 
Positive Ranks 
Critical Value P Value 
Caudate 1844.36 2061.86 Z= –7.916 p< 0.001 
Putamen 2236.47 3458.33 Z= –33.26 p< 0.001 
 
According to the bootstrapping analysis, there was no significant 
difference between the left and right caudate as the null hypothesis median fell 
within the confidence interval around the difference median.  The left putamen 
had a significantly higher median than the right putamen as the null hypothesis 
median fell outside the left-side confidence interval around the difference median.  
Due to the large scale of the graph, the null hypothesis median was not shown in 
order to more clearly show that the confidence intervals and the difference 
median all fall on the 151-mark.  Thus, the bootstrapping analysis and the 
Wilcoxon test were in agreement regarding the putamen.  However, for the 
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caudate, the bootstrapping analysis did not find the significant difference that the 
Wilcoxon test identified. 
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Figure 7. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Caudate in Subject 2. 
 
The H0 cannot be rejected as the right-sided limit of the confidence interval falls onto the 
same zero value as the H0 median.  To allow for visibility of both lines, the red 
confidence interval limit is shown as a dotted line superimposed upon the green H0 
median. 
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Figure 8. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Putamen in Subject 2. 
 
 
The difference median in this data set was so consistent, that only one value was 
calculated for every iteration.  The confidence intervals are shown as red dotted lines 
superimposed upon the yellow sample median.  The H0 median is not shown, as the 
scale required to present both the H0 median and the sample median in one image is 
too large to adequately visualize the results.  The H0 median is always on the zero value 
of the x-axis.
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Subject 3 
 
In the caudate, the mean rank was significantly higher for the negative 
ranks, meaning that the right caudate had significantly higher voxel intensities.  In 
the putamen, the mean rank was significantly higher for the negative ranks, 
meaning that the right putamen had significantly higher voxel intensities. 
 
Table 10. Analysis Between Hemispheres of Subject 3 Using Wilcoxon 
Signed-Rank Test. 
Region 
Tested 
 
Mean Rank of 
Negative Ranks 
Mean Rank of 
Positive Ranks 
Critical Value P Value 
Caudate 2052.80 1572.46 Z= –23.01 p< 0.001 
Putamen 2743.82 2608.56 Z= –2.831 p= 0.005 
 
According to the bootstrapping analysis, the right caudate had a 
significantly higher median than the left caudate as the null hypothesis median 
fell outside the right-side confidence interval around the difference median.  The 
left putamen had a significantly higher median than the right putamen as the null 
hypothesis median fell to the left side of the confidence interval around the 
difference median.  Thus, the bootstrapping analysis and the Wilcoxon test were 
in agreement regarding the caudate.  However, for the putamen, the 
bootstrapping analysis and the Wilcoxon test found different hemispheres to 
have significantly greater voxel intensities. 
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Figure 9. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Caudate in Subject 3. 
 
The green H0 median is on the zero value of the x-axis, which is at the far right of the 
graph. 
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Figure 10. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Putamen in Subject 3. 
 
The green H0 median is on the zero value of the x-axis, which is at the far left of the 
graph. 
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Subject 4 
The Wilcoxon signed-rank test did not find a significant difference between 
the mean rank of the positive ranks and of the negative ranks, meaning that it did 
not find the left and right caudates to be significantly different.  In the putamen, 
the mean rank was significantly higher for the negative ranks, meaning that the 
right putamen had significant higher voxel intensities. 
 
Table 11. Analysis Between Hemispheres of Subject 4 Using Wilcoxon 
Signed-Rank Test. 
Region 
Tested 
 
Mean Rank of 
Negative Ranks 
Mean Rank of 
Positive Ranks 
Critical Value P Value 
Caudate 1627.71 1688.43 Z= –0.020 p= 0.984 
Putamen 1976.79 1857.42 Z= –2.921 p= 0.003 
 
According to the bootstrapping analysis, the right caudate had a 
significantly higher median than the left caudate as the null hypothesis median 
fell outside the right-side confidence interval around the difference median.  
There was no significant difference between the left and right putamen as the null 
hypothesis median fell within the confidence interval around the difference 
median.  Thus, the bootstrapping analysis and the Wilcoxon tests were not in 
agreement regarding either region.  For the caudate, the Wilcoxon test appears 
to have missed the significant difference uncovered by the bootstrapping 
analysis.  For the putamen, the bootstrapping analysis appears not to have seen 
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the significant difference that the Wilcoxon test identified.
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Figure 11. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Caudate in Subject 4. 
 
The green H0 median is on the zero value of the x-axis, which is at the far right of the 
graph. 
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Figure 12. Bootstrapping Analysis of the Difference Median of the Left 
Versus Right Putamen in Subject 4. 
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DISCUSSION 
 
Overview 
The neurological study of PD through imaging is still in its infancy, despite 
its long clinical history.  When a clinical diagnosis of PD presents equivocally, the 
current form of diagnostic imaging is the SPECT DaT scan, which utilizes a 
radionuclide that binds to the dopamine transporter DAT in the striatum.  The 
goal of this thesis project was to propose a way to improve the poor resolution 
and lack of quantitative measure in the use of the SPECT scans through the 
coregistration of MPRAGE scans.  The hope is that this method can improve 
both the clinical diagnosis through imaging.  Overall, the data appeared generally 
consistent with the patient information, suggesting that the methodology has 
great potential for true and meaningful efficacy. 
The “more-affected hemisphere” was defined as the hemisphere 
contralateral to the side of the body on which the motor symptoms first 
presented, and the “less-affected hemisphere” was defined as the hemisphere 
ipsilateral to the side of motor symptom presentation.  For all four subjects, the 
total number of voxels in each region was similar between hemispheres (Table 
2).  For each more-affected hemispheric region in each subject, the range size 
was either similar to or less than the corresponding less-affected hemisphere 
region (Table 2).  This corresponded well with the side of onset of each patient’s 
disease, as it suggests that, despite the comparable sizes of the regions, the 
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intensities of the voxels in the more-affected hemisphere regions did not extend 
as high as in the less-affected hemisphere. 
 Though the subjects’ pericalcarine baselines varied greatly, they were 
similar between hemispheres within each subject (Tables 3-5).  In general, there 
was a smaller proportion of voxels that exceeded each level above the 
pericalcarine baseline in the more-affected hemisphere than in the left-affected 
hemisphere for both the caudate and the putamen in all four subjects (Table 3-5). 
 
Subject 1 
 In Subject 1, the proportion of voxels that exceeded each of the seven 
levels above the baseline was smaller in the left-hemisphere regions than in the 
right-hemisphere regions (Table 3).  This difference was more clearly seen in the 
AI data.  In both the caudate and the putamen, the AI was greater than 1 for both 
triple and quadruple the pericalcarine baseline (Table 7).  The left striatum in the 
subject’s scan was visibly less activated than the right striatum (Figure 1), which 
appropriately matched the left-hemisphere onset (right-body onset) of the 
subject’s PD.  The left caudate in Figure 1 showed very little red – the color 
intensity indicating the highest activation – and this reflected the low proportion of 
voxels with intensities above triple the pericalcarine baseline and the lack of 
voxels with intensities above quadruple the pericalcarine baseline in the left 
caudate as seen in Table 3.  The left putamen in Figure 1 was less consistently 
red, i.e. less highly activated, than the right putamen; this matched the greater 
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proportion of voxels that exceeded triple and quadruple the pericalcarine 
baseline in the right putamen (Table 3). 
The Wilcoxon Signed-Rank test found that the mean rank in Subject 1 was 
significantly higher for the positive ranks of the caudate and significantly higher 
for the negative ranks of the putamen, meaning that the left caudate and the right 
putamen had significantly higher voxel intensities than their respective 
counterparts (Table 8).  The bootstrapping analysis found the left caudate to 
have significantly greater values than the right caudate as the null hypothesis 
median fell to the left of the confidence interval around the difference median 
(Figure 5).  This result supported the conclusion of the associated Wilcoxon test. 
On the other hand, the bootstrapping analysis found that the right putamen had 
significantly greater voxel intensities than the left putamen as the null hypothesis 
difference mean fell well to the right of the sample difference mean’s confidence 
interval (Figure 6).  This result was in agreement with the conclusion of the 
Wilcoxon test.  The result of the latter bootstrapping analysis was also consistent 
with the quantification of the data in Table 3, the AI values in Table 7, and the 
visible asymmetry in Figure 1. 
The data collected on Subject 1’s caudate (Table 3, Table 7, and Figure 1) 
were consistent with the subject’s right-body, left-hemisphere onset of PD (Table 
1).  The statistical analyses on the caudate were not supportive; however, this 
may suggest that the patient’s greater right caudate dopaminergic loss was 
simply not implicated in the right-body onset of motor symptoms, hence its 
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inconsistency with the side of onset.  Dopaminergic loss in the caudate is not 
generally associated with motor symptoms in PD (9).  All the data collected on 
this subject’s putamen as well as the associated statistical analyses points to 
greater loss of dopaminergic activation in the left hemisphere corresponding to 
right-body disease onset, and this was consistent with the patient’s described 
side of onset as seen in Table 1.  
 
Subject 2 
 In Subject 2, the proportion of voxels whose intensities exceeded each of 
the four levels above the pericalcarine baseline was smaller in the left caudate 
than in the right caudate (Table 4).  There was a greater proportion of voxels 
whose intensities exceed the baseline and twice the baseline in the right 
putamen than in the left putamen; however, interestingly, the proportion of voxels 
whose intensities exceeded triple, quadruple, and quintuple the pericalcarine 
baseline was slightly greater in the left putamen than in the right (Table 4).  
Accordingly, the AI values for both thresholds were greater than 1 for the caudate 
and were less than 1 for the putamen (Table 7).  These data may appear 
somewhat ambiguous, and Figure 2, at first glance, mirrors this.  Upon closer 
look, though, the left-hemisphere-onset (right-body onset) nature of Subject 2’s 
disease becomes clear.  In the right putamen, the top 2% of voxel intensities 
exceeded 7 times the baseline, but, in the left putamen, the top 2% only 
exceeded 6 times the baseline (Table 4).  These higher intensity voxels present 
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in the right putamen have already degenerated in the left putamen.  In the scan, 
the left putamen tail was no longer visible, and the left caudate was not as 
consistently highly activated – indicated by less red coloring – than the right 
caudate (Figure 2). 
 The Wilcoxon Signed-Rank test in Subject 2 found that the mean rank was 
significantly higher for the positive ranks in both the caudate and the putamen, 
meaning that the left hemisphere regions of the striatum had significantly higher 
voxel intensities (Table 9).  The bootstrapping analysis found no significant 
difference between the left and right caudate as the null hypothesis median fell 
within the confidence interval around the median (Figure 7).  This suggests that 
the conclusion of the Wilcoxon test was simply due to the truncation of data 
rather than a true difference.  However, the bootstrapping analysis found that the 
left putamen had significantly higher intensity values as the null hypothesis fell to 
the left of the confidence interval around the difference median (Figure 8).  This 
supports the Wilcoxon test’s conclusion as well as the AI values for the putamen 
of this subject (Table 7).  The bootstrapping and the Wilcoxon test results were 
not consistent with the left-hemisphere, right-body disease onset of this subject 
(Table 1). 
If the bootstrapping analysis is accurate in finding that the right putamen 
has lower voxel intensities than the left putamen, then, unfortunately, this leaves 
the incongruence between the right-body disease onset and the greater 
dopaminergic loss in the right putamen unexplained.  The accuracy of the 
 70 
bootstrapping analysis was double-checked because the consistency of the 
difference median is unusual.  There may be some inherent characteristic of the 
voxel intensities or of the patient’s brain that can account for this apparent 
discrepancy, but that is out of the scope of this project.  The bootstrapping 
analysis did not find a significant difference between the intensity values of the 
left and right caudate.  Therefore, the left caudate may still have lower intensity 
values (Table 4, Table 7), but the difference does not hold statistical significance.  
Possibly, this difference will hold statistical significance later in the disease 
progression. 
 
Subject 3 
In Subject 3, the proportion of voxels whose intensities exceeded each of 
the seven thresholds above the pericalcarine baseline, as seen in Table 5, is 
smaller in the right putamen than in the left putamen for all levels above the 
baseline.  This is consistent with the patient’s left-body disease onset.  The right 
caudate has a smaller proportion of voxels with intensities that exceeded each 
threshold until 4 times the baseline (Table 5).  At this point, there was 
inexplicably a greater proportion of voxels with intensities that exceeded this 
threshold.  However, at the next threshold, the proportion in the right caudate 
was only marginally larger (Table 5).  Indeed, except for the caudate AI at the 
quadruple baseline threshold, the AI values were all less than 1, as was 
expected for a right-hemisphere disease onset (left-body onset) (Table 7).  In the 
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scan in Figure 3, more of the right caudate’s voxels were indicated as highly 
activated by the red coloring, though the left and right caudate were still roughly 
the same size.  This corresponds to the data in Table 5: the proportion of voxels 
was greater in the left caudate whose intensities exceeded twice the 
pericalcarine baseline but greater in the right caudate for quadruple the baseline, 
and the proportions were similar for the other thresholds.  The left-body onset 
was more clearly explained when contrasting the putamen between 
hemispheres.  Although the left putamen in Figure 3 was not very highly 
activated, the right putamen was not present at all on the scan.  This 
corresponded to the AI values in Table 7, which were less than 1 for both 
thresholds. 
The Wilcoxon Signed-Rank test found that the mean rank in Subject 3 for 
the negative ranks was significantly higher for both striatal regions, meaning that 
the right caudate and the right putamen had significantly higher voxel intensities 
than their respective counterparts (Table 10).  The bootstrapping analysis, on the 
other hand, found that the right caudate and the left putamen had significantly 
greater voxel intensities than the left caudate and the right putamen.  For the 
caudate, the null hypothesis difference median of zero fell to the right of the 
confidence interval around the sample difference median (Figure 9).  Thus, for 
the caudate, the bootstrapping analysis and the Wilcoxon test were in 
agreement.  For the putamen, the null hypothesis difference median of zero fell 
to the left of the confidence interval around the difference median (Figure 10).  
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This oppugns the conclusion of the Wilcoxon test and suggests that its contrary 
result was due to the truncation of data that would have otherwise exerted a 
meaningful influence on the sample comparison. 
Although the bootstrapping analysis of the putamen was not in agreement 
with the Wilcoxon test conclusion, it was actually more consistent with the 
quantification of the data (Table 5), the AI values (Table 7), the SPECT scan 
(Figure 3), and the patient’s left-body (right-hemisphere) onset of PD.  Neither 
the bootstrapping analysis nor the Wilcoxon test of the subject’s caudate 
produced results consistent with the rest of the quantification data (Table 5), but 
this may be attributed to the lack of statistical significance of the quantification 
data.  Although neither statistical test offered conclusions consistent with the 
patient’s side of disease onset (Table 1), the caudate is not usually considered to 
be implicated in the motor symptoms of PD (9). 
 
Subject 4 
 In Subject 4, the proportion of voxels whose intensities exceeded each of 
the seven thresholds above the pericalcarine baseline was greater in the right 
hemisphere for both regions (Table 6), as was expected for this patient’s right-
body disease onset (left-hemisphere onset).  There were no voxels in any region 
that exceeded quadruple the pericalcarine baseline, and, as such, there were no 
AI values for this threshold, but, for the lower threshold, both the AI values were, 
accordingly, greater than 1 (Table 7).  In the subject’s scan, the left striatum was 
 73 
visibly less activated than the right striatum, as evidenced by the clearly fewer 
number of red- and orange-colored voxels in the left hemisphere (Figure 4), 
which corresponded well with the right-body onset of the patient’s PD.  The AI 
value for the putamen was much greater than that of the caudate in this subject 
(Table 7), and, accordingly, the difference in activation between the left and right 
putamen regions appeared greater on the scan in Figure 4 than did the 
difference in activation between the left and right caudate.  In fact, while there 
was still a small portion of the left caudate being highly activated, there was very 
little left putamen visible at all. 
 The Wilcoxon Signed-Rank test in Subject 4 found that the mean rank for 
the putamen was significantly higher for the negative ranks, meaning that the 
right putamen had significantly higher voxel intensities (Table 11).  The right 
caudate was not significantly different from the left caudate according to the 
Wilcoxon test (Table 11).  Interestingly, the bootstrapping analysis did not 
support either of these conclusions.  For the putamen comparison, the null 
hypothesis difference median fell within the confidence interval of the sample 
difference median (Figure 12).  This suggests that the significant difference 
uncovered by the Wilcoxon test may have been a false positive arising from the 
fortuitous truncation of data.  However, it is possible that as the patient’s disease 
progresses, this difference will become statistically significant.  Regarding the 
caudate, the null hypothesis difference median fell to the right of the confidence 
interval around the difference median (Figure 11). This means that the right 
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caudate voxel intensities were significantly higher than the left caudate voxel 
intensities.  The truncation of data most likely caused the Wilcoxon test to instead 
find no significant difference between the regions. 
Despite the clear asymmetry in the proportions calculated for both regions 
(Table 6), in the AI values in Table 7, and in Figure 4, neither the Wilcoxon test of 
the caudate data nor the bootstrapping analysis of the putamen supported the 
perceived greater left-hemisphere loss of dopaminergic activation.  The subject’s 
PD is already at Hoehn & Yahr Stage 2, so the lack of significant difference 
between the left and right putamen seen in the bootstrapping analysis could be 
due to his disease having progressed far enough that the less-affected 
hemisphere’s dopaminergic loss has begun to catch up to the right hemisphere’s. 
 
Further Interpretation 
 Each subject’s data can be further interpreted in the light of the patient’s 
clinical history, which was reported in Table 1.  Subject 1, for example, has had a 
PD diagnosis for 7 years and is already at Hoehn & Yahr Stage 3 of his disease, 
while Subject 2 was only diagnosed 2 years ago and is at Hoehn & Yahr Stage 1.  
Subject 2 had voxel intensities up to 6 times the pericalcarine in all four regions 
of his scan (Table 4), while the highest threshold above which Subject 1 has 
voxel intensities in every region is 3 times his pericalcarine baseline (Table 3).  
This reflects nicely how these two subjects are at very different stages in their 
disease progression.  Subject 4, on the other hand, has a much more slowly 
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progressing disease than Subject 1 as there were even smaller proportions of 
voxels whose intensities exceeded triple the pericalcarine baseline (Table 6) than 
is seen in Subject 1, and yet his disease is only at Hoehn & Yahr Stage 2.  
Subject 3, though, has the slowest disease progression of all four participants as 
his voxel intensities surpassed 5 times the pericalcarine baseline in all four 
regions (Table 5), and he is only at Hoehn & Yahr stage 1, though he was 
diagnosed with PD 16 years ago.  Though these associations between disease 
severity and the quantification data are certainly intriguing, being able to show 
statistical significance would strengthen the validity of these relationships.  
Hopefully, larger studies in the future can statistically confirm that longitudinal 
quantification data of patient’s SPECT DaT scans matches their clinical disease 
progression. 
 
A Presentation of the Method’s Utility 
Subject 3 offers an opportunity to present an important potential utility for 
this method.  As noted in Table 1, this patient was initially diagnosed with left-
body onset of PD; however, the side of onset was later contested.  He had motor 
symptoms presenting on both sides of the body, which oppugned the diagnosis 
of PD.  A SPECT scan was ordered to establish the accuracy of a PD diagnosis 
and to shed light on the side of disease onset.  When the scan was clinically 
assessed, the radiologist concluded that there was decreased activation in the 
left putamen, implying right-body disease onset.  For the sake of continuity, the 
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side of onset listed for this subject in this project (left-body onset; see Table 1) 
was the one initially reported by the patient, just as was the case for the other 
three participants.  Determining which hemisphere has greater dopaminergic loss 
(particularly in the putamen) would help to illuminate whether the initial 
diagnostician’s left-body onset diagnosis or the radiologist’s suggestion of right-
body onset is more accurate.  
There is evidence that the patient’s right putamen exhibited greater 
dopaminergic loss than the left putamen, corresponding to a left-body disease 
onset.  First of all, most of the percentages of voxels with intensities exceeding 
pericalcarine thresholds supported greater dopaminergic loss in the right 
hemisphere.  For every level above the pericalcarine baseline, the percentage of 
voxels whose intensities exceeded three times the pericalcarine baseline was 
greater in the left putamen than in the right putamen (Table 5).  (The percentage 
of voxels with intensities exceeding two and three times the pericalcarine 
baseline was higher in the left caudate (Table 5).)  Additionally, the majority of 
the AI values supported greater dopaminergic loss in the right hemisphere.  The 
AI values for three times the pericalcarine baseline were less than 1 for both the 
caudate and the putamen (Table 7).  This indicated greater proportions of voxels 
with intensities exceeding the thresholds in the left hemispheric regions.  The AI 
value for four times the pericalcarine baseline in the putamen was less than 1 as 
well (Table 7), also suggesting a greater proportion of voxels with intensities 
exceeding the threshold in the left hemisphere.  Finally, the left putamen, though 
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not very highly activated, could still be seen in the scan (Figure 3), whereas the 
right putamen was not visible at all.  This greater right-hemisphere loss of 
dopaminergic terminals seen in much of the data is consistent with the initial 
determination of left-body onset of PD.  Furthermore, the bootstrapping analysis 
showed that the right putamen had lower voxel intensities, corresponding to the 
greater right-hemisphere dopaminergic loss seen in left-body disease onset. 
On the other hand, there is also evidence supporting a right-body onset 
PD diagnosis.  Although the quantification of the data does not seem to endorse 
the right-body onset as much as the left-body onset, the statistical testing offers a 
different result.  The Wilcoxon tests on the caudate and the putamen both 
reported reduced intensities of voxels in the left hemisphere, and the latter 
corresponds to right-body disease onset.  Moreover, the radiologist who read the 
patient’s scan evaluated the scan as having greater right-hemispheric activation 
to support a right-body onset of PD.  Interestingly, this is in fairly direct 
contradiction to the quantification of the putamen’s data.  
The present understanding of PD is far from perfect, though advances in 
neuroimaging have precipitated further insights into the neurology of the disease.  
Although there is much still to be explained about the etiology and progression of 
PD, the current consensus is that the putamen is more heavily involved in the 
motor aspects of the disease, while the caudate is more implicated in the 
cognitive and affective symptoms (9).  This dichotomous understanding of the 
role of the striatum in PD is poised to change with new information from 
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neuroimaging.  However, if the respective propensities of the caudate and the 
putamen remain true, then they may offer an explanation of this subject’s data.  
The quantification of the data as well as the scan and the statistical testing 
suggest greater dopaminergic loss in the right putamen.  If the putamen is indeed 
more associated with motor symptoms, and the right putamen reveals greater 
dopaminergic loss, then this corroborates the initial diagnosis of left-body onset 
PD.  If the caudate is less implicated in motor dysfunction than the putamen, then 
the greater decrease in dopaminergic activation exhibited by the right caudate 
than the left caudate may not have necessarily produced the motor symptoms 
that instigated the clinical diagnosis of PD.  In this case, the initial diagnostician 
was correct in his observation of left-body onset, and the radiologist was 
mistaken in subjectively concluding greater left putamen decrease in activation to 
confirm right-body onset of PD.  Thus, the quantification of the scan elucidated 
the nature of the patient’s asymmetrical striatal dopaminergic loss where a 
qualitative judgment of asymmetrical activation in the scan could not. 
 
Potential for Improvement 
 This project has a number of limitations that, for the most part, can and 
should be remedied in future studies validating this methodology.  An important 
consideration is the partial volume effect (PVE).  The PVE accounts for the errors 
that arise from the inherently poor spatial resolution of the SPECT scan.  The low 
spatial resolution blurs the image such that areas of true activation are spread 
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out into neighboring voxels (32).  This decreases the intensities of the center of 
activation while increasing the intensity of the surrounding voxels, thereby 
detracting from the accuracy of the location and intensity of dopaminergic uptake 
(32).  Partial volume correction (PVC) corrects the errors due to the PVE.  
Running the intensity values through a PVC algorithm, for which there are 
software packages available written specifically for SPECT scans, would 
increase confidence in the accuracy of the subsequent quantification data (33).  It 
is important to note that the statistical results which did not support the 
quantification of the data or which did not support the side of onset described by 
the patient may in fact affirm the patient’s side of disease onset once they have 
been partial-volume corrected.  This methodology also needs to be validated on 
a larger scale.  A study with many more than the four subjects being used in this 
project would permit the use of more robust statistical testing.  In addition, 
validating this method in long-term settings would support its use in longitudinal 
investigations.  Unfortunately, an unavoidable drawback of this method is that it 
can currently only be performed on subjects who have no contraindications to 
MRI or SPECT scanning.  
 
Looking Forward 
Validation of this methodology with larger studies and the use of robust 
statistical testing will advance its use in a number of different environments.  As 
mentioned earlier, longitudinal use may help to more quantitatively measure the 
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changes in dopaminergic activation in the striatum in order to investigate clinical 
disease progression in more detail.  This methodology can lend its quantitative 
nature to the standardization of PD diagnosis via SPECT imaging as it can tease 
out asymmetry and deactivation information that may not be otherwise apparent 
through solely visually inspecting SPECT scans.  This capability may lead both to 
more accurate differential diagnoses of the various extrapyramidal 
neurodegenerative diseases such as MSA and PSP and to earlier identification 
of PD and subsequently initiation of treatment or preventative measures.  Finally, 
the method will bring quantification of SPECT data to research studies utilizing 
SPECT scans to study all aspects of PD.  For instance, the quantification can be 
performed with even smaller striatal subregions to give an increasingly more 
detailed picture of the dopaminergic changes occurring due to the disease.  The 
lab plans to use this SPECT quantification methodology in conjunction with other 
imaging modalities, including fMRI and DTI, to study changes in cognition and 
affect in patients with PD.  The ability to quantify SPECT scans will be an 
important advantage both to diagnosticians and to researchers involved with PD. 
 
Conclusion 
 Between the four subjects, there were sixteen regions being quantified – 
the left and right caudate, and the left and right putamen.  As the putamen is the 
region implicated in the motor symptoms of PD (9), only 8 of these quantified 
regions are relevant to the patient’s side of onset.  The quantification of the data 
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supported the side of onset in all eight putamen regions.  Sixteen statistical tests 
were run: a Wilcoxon signed-rank test and a bootstrapping analysis each for the 
caudate and the putamen in every subject.  Although the Wilcoxon tests did not 
generally produce results consistent with the rest of the quantification data, the 
bootstrapping analyses were supportive of the quantification data in six of the 
eight analyses.  The scans were clearly consistent with the quantification of the 
data and the side of disease onset in two subjects.  In a third subject, the scan 
was reflective of the quantification of the data and of the side of onset once it was 
explored more deeply.  In one subject, though, the scan was reflective of the side 
of onset once considered more carefully but not of the quantification data.  
Overall, the results of this project substantiate the side of symptom onset 
described by the patients and their clinicians.  With the inclusion of PVC, the 
results will most likely be even more accurate.  In summary, this thesis project 
has shown the great potential of this methodology. 
 
 82 
 
LIST OF JOURNAL ABBREVIATIONS 
 
Behav Brain Res    Behavioural Brain Research 
BMJ      British Medical Journal 
Cereb Cortex    Cerebral Cortex 
Eur J Nucl Med Mol Imaging European Journal of Nuclear Medicine 
and Molecular Imaging 
IEEE Trans Med Imaging   IEEE Transactions on Medical Imaging 
J Biomed Biotechnol   Journal of Biomedicine and 
Biotechnology 
J Nucl Med     Journal of Nuclear Medicine 
J Neurol Neurosurg Psychiatry  Journal of Neurology, Neurosurgery, 
and Psychiatry 
Lancet Neurol    The Lancet: Neurology 
Mov Disord     Movement Disorders 
Neurobiol Dis    Neurobiology of Disease 
Neurol Sci     Neurological Sciences 
Neurotox Res    Neurotoxicity Research 
Parkinsonism Relat Disord   Parkinsonism & Related Disorders 
Proc Natl Acad Sci USA   Proceedings of the National Academy of 
Sciences 
 83 
 
REFERENCES 
 
1. Factor SA & Weiner WJ. Parkinson's Disease : Diagnosis and Medical 
Management (2nd Edition). New York, USA: Demos Medical Publishing, 
2007. 
 
2. Wang L, Zhang Q, Huanbin L, and Zhang H. SPECT Molecular Imaging in 
Parkinson’s Disease. J Biomed Biotechnol. 2012; 2012: 1-11. 
 
3. Simuni T & Pahwa R. Parkinson's Disease. Cary, NC, USA: Oxford 
University Press, 2009. 
 
4. Bajaj N, Hauser RA, and Grachev ID. Clinical utility of dopamine 
transporter single photon emission CT (DaT-SPECT) with (123I)ioflupane in 
diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 
2013; 0: 1-8. 
 
5. Eidelberg D. Imaging in Parkinson’s Disease. New York: Oxford University 
Press, USA, 2011. 
 
6. Lees AJ. Unresolved issues relating to the shaking palsy on the 
celebration of James Parkinson's 250th birthday. Mov Disord. 2007; 22: 
S327-34. 
 
7. Longstaff A. BIOS Instant Notes in Neuroscience. Abingdon, Oxon: Taylor 
& Francis, 2011. 
 
8. Coffey CE & Cummings JL. The American Psychiatric Publishing 
Textbook of Geriatric Neuropsychiatry. Arlington, VA: American 
Psychiatric Publishing, 2011. 
 
9. Grahn JA, Parkinson JA, and Owen AM. The role of the basal ganglia in 
learning and memory: Neuropsychological studies. Behav Brain Res. 
2009; 199: 53-60.  
 
10. Fahn S, Elton R, Members of the UPDRS Development Committee. 
Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne 
DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, Vol 
2. Florham Park, NJ: Macmillan Health Care Information, 1987. 
 
 84 
11. Leentjens AFG, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, 
Starkstein SE, et al.  Apathy and Anhedonia Ratings Scales in Parkinson’s 
Disease: Critique and Recommendations. Mov Disord. 2008; 23: 2004-14. 
 
12. Burn DJ. Beyond the iron mask: Towards better recognition and treatment 
of depression associated with Parkinson’s disease. Mov Disord. 2002; 17: 
445-454. 
 
13. Chase TN. Apathy in neuropsychiatric disease: Diagnosis, 
pathophysiology, and treatment. Neurotox Res. 2011; 19: 266-278. 
 
14. Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, and Di 
Benedetto P. Evaluation of anxiety in Parkinson’s disease with some 
commonly used rating scales. Neurol Sci. 2007; 28: 270-275. 
 
15. Kehagia AA, Barker RA, and Robbins TW. Neuropsychological and clinical 
heterogeneity of cognitive impairment and dementia in patients with 
Parkinson’s disease. Lancet Neurol. 2010; 9: 1200-1213. 
 
16. Kalf JG, de Swart BJM, Bloem BR, and Munneke M. Prevalence of 
oropharyngeal dysphagia in Parkinson’s disease: A meta-analysis. 
Parkinsonism Relat Disord. 2012; 18: 311-315. 
 
17. Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, and 
Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s 
disease. Neurobiol Dis. 2012; 46: 565-571.  
 
18. Berger A. Magnetic Resonance Imaging. BMJ. 2002; 324: 35. 
 
19. Brant-Zawadzki M, Gillan GD, and Nitz WR. MP RAGE: a three-
dimensional, T1-weighted, gradient-echo sequence – initial experience in 
the brain. Radiology. 1992; 182: 769-75. 
 
20. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et 
al. [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of 
dopamine transporters in hemi-Parkinson’s disease. Neurology. 1996; 46: 
231-237. 
 
21. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. 
Iodine-123-b-CIT and Iodine-123-FPCIT SPECT Measurement of 
Dopamine Transporters in Healthy Subjects and Parkinson's Patients. J 
Nucl Med. 1998; 39: 1500-1508. 
 
 85 
22. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, et al. 
Dopamine Transporter Imaging Is Associated With Long-Term Outcomes 
in Parkinson’s Disease. Mov Disord. 2012; 27: 1392-1397. 
 
23. Ségonne F, Pacheco J, and Fischl B. Geometrically accurate topology-
correction of cortical surfaces using nonseparating loops. IEEE Trans Med 
Imaging. 2007; 26: 518-529. 
 
24. Fischl B, and Dale AM. Measuring the thickness of the human cerebral 
cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000; 
97: 11050-11055. 
 
25. Ségonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, and Fischl 
B. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 
2004; 22: 1060-1075. 
 
26. Fischl B, Salat DH, van der Kouwe AJ, Makris N, Ségonne F, Quinn BT, 
and Dale AM. Sequence-independent segmentation of magnetic 
resonance images. Neuroimage. 2004; 23: S69-S84. 
 
27. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, 
et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 
2004; 14: 11-22. 
 
28. Innis RB, Seibyl JP, Scanley BE, Laurelle M, Abi-Dargham A, Wallace E, 
et al. Single photon emission computed tomographic imaging 
demonstrates loss of striatal dopamine transporters in Parkinson disease. 
Proc Natl Acad Sci USA. 1993; 90: 11965-11969. 
 
29. Greve D & Fischl B. Accurate and robust brain image alignment using 
boundary-based registration. NeuroImage. 2009; 48: 63-72. 
 
30. IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp. 
 
31. MATLAB and Statistics Toolbox Release 2010b, The MathWorks, Inc., 
Natick, Massachusetts, United States. 
 
32. “Partial-Volume Correction (PVC).” PBAS. PMOD Technologies Ltd. 2011. 
Web. 28 Jan. 2015. 
 
33. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, and Nobili F. 
The basal ganglia matching tools package for striatal uptake semi-
 86 
quantification: description and validation. Eur J Nucl Med Mol Imaging. 
2007; 34: 1240–1253. 
 87 
 
CURRICULUM VITAE 
 
KARISHMA SMART 
CONTACT INFORMATION 
 
30 E. Concord St., Apt. 24 
Boston, MA 02118 
Email: klsmart@bu.edu  
Alternate Email: karishma@thesmarts.com 
 
Year of Birth: 1990 
 
EDUCATION 
 
Boston University School of Medicine, Boston, MA 
M.S., Medical Science 
May 2015 
 
Cornell University College of Arts and Sciences, Ithaca, NY 
B.A., Biological Sciences 
May 2013 
 
The Lawrenceville School, Lawrenceville, NJ 
Secondary School 
May 2009 
 
 
RESEARCH EXPERIENCE 
 
Summer of 2008 and Summer of 2009 
Interned in a laboratory in the Microbiology Department of the Weill Cornell 
Medical School research colon cancer under Francis Barany, PhD.  Procedures 
included growing cell cultures and performing PCR experiments, among others. 
Academic Year 2010-2011 
Spent second undergraduate year at Cornell as a research assistant in a Social 
Psychology laboratory studying the effects of emotional induction on judgment 
under Tom Gilovich, PhD. 
July 2014-Present 
Full-time research work for my Master’s thesis in the McNamara Lab, a BU 
Department of Neurology lab at the Boston VA Hospital in Jamaica Plain under 
 88 
Patrick McNamara, PhD. I also worked with Dr. Edward Modestino, PhD, another 
member of the lab.  For my Master’s thesis, I developed a method of SPECT 
scan quantification to increase the objectivity of Parkinson’s disease diagnosis. I 
also administer neuropsychological testing to participants and schedule patient 
visits and MRI scans for Dr. McNamara’s Cognition and Parkinson’s Project. I 
was responsible for writing and compiling an NIH R01 grant application that Dr. 
Modestino submitted February 2015. I have also attended the MGH-Martinos 
Center FreeSurfer course, which teaches how to use the FreeSurfer 
neuroimaging analysis software. 
 
TEACHING EXPERIENCE 
 
Cornell University 
Teaching Assistant for Introductory Physics for 4 semesters (Fall 2010, Spring 
2011, Fall 2011, Spring 2012). 
 
Boston University 
Teaching Assistant for Behavioral and Biological Aspects of Stress and Trauma 
(Fall 2014). 
 
Teaching Assistant for Critical Reading and Analyses of the Medical Literature 
(Spring 2015). 
 
Trainings 
I attended the FreeSurfer training course at MGH-Martinos Center in Charleston, 
MA in October 2014. There, I formally learned how to use the various tools in the 
FreeSurfer software package to supplement the knowledge I acquired since 
starting my thesis work. 
 
Internships 
Nine-week internship during the summer of 2012 in the Morristown Medical 
Center Summer Student Fellowship, which involved being exposed to various 
aspects of hospital medicine.  These areas included morning rounds, observing 
surgeries of all kinds, shadowing a pathologist, watching an autopsy, and much 
more. 
 
Extracurricular Activities 
! I was on Cornell Big Red Raas for 4 years as a senior member.  Cornell 
Big Red Raas is a competitive team that performs an Indian folk dance 
called garba-raas from the Western state of Gujarat.  The team performs 
on campus and competes against other collegiate teams across the 
country. I hope to pursue this activity again in the near future. 
! I was a member of the Society for India, a cultural association at Cornell 
University that tries to spread awareness of and appreciation for Indian 
 89 
culture.  I participated in events and choreograph segments of my class 
dance in the annual Diya Jale Diwali celebration show. 
